• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Mark Cziraky, PharmD, CLS: The Future of Biosimilars


Mark Cziraky, PharmD, CLS, describes what he sees as the future of the biosimilars space.


What do you see as the future for the biosimilar space?

Well, I think a big part of it is we’re hopeful that these therapies become a big opportunity to reduce costs in the healthcare system while getting the intended benefits of these therapies.

You look at the generic marketplace and biopharmaceuticals in general, and while it’s taken some time, there are significant cost savings to be appreciated from using generic therapies. So, if you apply that to the biosimilar marketplace, and hopefully we’ll see again significant cost-reductions in the acquisition costs in the use of these therapies, and we’ll see benefits in that area too.

Related Videos
Lakesha Farmer, PharmD
Lakesha Farmer from Cencora
Jeffrey Casberg, RPh, MS.
Adam Colborn, JD.
Legal scale weighs profit as greater than medical treatment
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Related Content
© 2024 MJH Life Sciences

All rights reserved.